Huadong Medicine Co Ltd
SZSE:000963
Huadong Medicine Co Ltd
Income from Continuing Operations
Huadong Medicine Co Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Huadong Medicine Co Ltd
SZSE:000963
|
Income from Continuing Operations
¥2.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
14%
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Income from Continuing Operations
¥15B
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
15%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Income from Continuing Operations
¥5.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Income from Continuing Operations
¥2.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
16%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Income from Continuing Operations
¥2.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
18%
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Income from Continuing Operations
¥1.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
See Also
What is Huadong Medicine Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
2.9B
CNY
Based on the financial report for Mar 31, 2024, Huadong Medicine Co Ltd's Income from Continuing Operations amounts to 2.9B CNY.
What is Huadong Medicine Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
14%
Over the last year, the Income from Continuing Operations growth was 14%. The average annual Income from Continuing Operations growth rates for Huadong Medicine Co Ltd have been 5% over the past three years , 2% over the past five years , and 14% over the past ten years .